OAC
SABS icon

OMERS Administration Corp’s SAB Biotherapeutics SABS Stock Holding History

OMERS Administration Corp’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$114K Sell
29,700
-12,300
-29% -$49K ﹤0.01% 999
2025
Q4 		$157K Buy
+42,000
New +$138K ﹤0.01% 940

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OMERS Administration Corp's SABS Position: Q1 2026 in Review

OMERS Administration Corp reduced its SAB Biotherapeutics (SABS) stake by 29% in Q1 2026, selling an estimated $49K and leaving 29,700 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #999.

OMERS Administration Corp first reported a position in SABS in Q4 2025 and has held it in 2 quarters since. The position peaked at $157K in Q4 2025. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • OMERS Administration Corp held 29,700 shares of SAB Biotherapeutics worth $114K as of Q1 2026.
  • OMERS Administration Corp sold 12,300 SAB Biotherapeutics shares in Q1 2026, an estimated $49K.
  • SAB Biotherapeutics made up ﹤0.01% of OMERS Administration Corp's portfolio in Q1 2026, its #999 holding.
  • OMERS Administration Corp first reported a position in SAB Biotherapeutics in Q4 2025 and has held it in 2 quarters since.
  • OMERS Administration Corp's SAB Biotherapeutics position peaked at $157K in Q4 2025.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.